111 completed, 43 terminated, 30 recruiting, 15 unknown. 225 Phase 1, 67 Phase 2.
Follow Metastatic Cancer: new trials by email Literature Review of Metastatic Cancer trials Research Report on Metastatic Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy 177Lu-PSMA-I&T - escalating renal absorbed dose, 177Lu-PSMA-I&T - recommended phase 2 regime - Cancer, Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | CHU de Quebec-Universite Laval | 500 | 2028-03-01 | 2025-03-30 |
| Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer 90Y-NM600 - Metastatic Cancer | Phase 1 | Recruiting | University of Wisconsin, Madison | 60 | 2026-11-01 | 2026-08-19 |
| STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study Ablative radiation treatment - Advanced Solid Tumor, Metastatic Cancer | Phase 1 | Recruiting | University of Illinois at Chicago | 28 | 2025-12-08 | 2026-03-02 |
| Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases. 68Ga-FXX489, Positron Emission Tomography (PET) imaging, Gallium-68 labelled (68Ga-) FAP-2286 - Tumor, Metastatic Cancer | Phase 1 | Recruiting | Yi Tian | 30 | 2025-09-11 | 2026-04-03 |
| CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer [18F]CSB-321 - Metastatic Cancer, Unresectable Solid Tumor | Phase 1 | Not yet recruiting | Cytosite Biopharma Inc. | 40 | 2025-09-01 | 2025-07-09 |
| Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases Bevacizumab - Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Active not recruiting | Pardis Noor Medical Imaging and Cancer Center | 40 | 2025-06-01 | 2026-09-16 |
| SLV-154 Treatment of Advanced Cancers SLV-154 - Advanced Cancer, Advanced Solid Tumor | Phase 1 | Recruiting | Solve Therapeutics | 250 | 2025-05-14 | 2026-09-22 |
| A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors BGB-B3227, Tislelizumab, Chemotherapy - Advanced Cancer, Advanced Solid Tumor | Phase 1 | Terminated | BeiGene | 35 | 2024-09-11 | 2026-03-16 |
| A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors ALTA2618 - Cancer, Breast Cancer | Phase 1 | Active not recruiting | Alterome Therapeutics, Inc. | 110 | 2024-08-22 | 2026-07-15 |
| Treatment of Cancer With Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound Histotripsy HIFU-HT, ICI - Cancer, Metastatic Cancer | Phase 1 | Recruiting | UMC Utrecht | 24 | 2024-07-26 | 2026-02-18 |
| Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors Intraperitoneal infusion of FAST CEA-targeted CAR-T - Colorectal Cancer, Stomach Cancer | Phase 1 | Recruiting | Weijia Fang, MD | 18 | 2024-07-24 | 2026-01-23 |
| A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors PTX-912 - Advanced Cancer, Solid Tumor | Phase 1 | Recruiting | Proviva Therapeutics, Inc. | 26 | 2024-06-11 | 2024-11-07 |
| Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. - Metastatic Cancer | Phase 1 | Recruiting | University of California, Davis | 40 | 2024-04-01 | 2026-09-11 |
| Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer RP-6306, Carboplatin, Paclitaxel - Recurrent Ovarian Cancer, Recurrent Uterine Cancer | Phase 1 | Active not recruiting | University Health Network, Toronto | 6 | 2024-03-20 | 2026-06-10 |
| A Study of MGC026 in Participants With Advanced Solid Tumors MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab - Advanced Solid Tumor, Advanced Cancer | Phase 1 | Recruiting | MacroGenics | 394 | 2024-03-06 | 2026-10-28 |
| A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer CD70 CAR-T cells - Ovarian Cancer, Cervix Cancer | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 36 | 2024-01-10 | 2024-01-22 |
| Study of OB-002 in Patients With Refractory Metastatic Cancer OB-002 - Metastatic Cancer, Metastatic Colorectal Cancer | Phase 1 | Withdrawn | Orion Biotechnology Polska Sp. z o.o. | 2024-01-01 | 2025-04-09 | |
| A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer [177Lu]Lu-SN201 - Solid Tumor, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | Spago Nanomedical AB | 90 | 2023-12-06 | 2025-11-20 |
| A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors CD70 CAR-T cells - Renal Cell Carcinoma, Ovarian Cancer | Phase 1 | Unknown | Chongqing Precision Biotech Co., Ltd | 48 | 2023-11-30 | 2023-11-08 |
| Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases Azeliragon, Stereotactic radiosurgery, Corticosteroid - Cancer, Metastasis | Phase 1 / Phase 2 | Suspended | Baptist Health South Florida | 46 | 2023-11-17 | 2026-06-16 |
Showing 20 of 225. Sign in to see all of them.
Neoplasm Metastasis (225) · Neoplasms (49) · Carcinoma, Non-Small-Cell Lung (43) · Colorectal Neoplasms (39) · Melanoma (37) · Breast Neoplasms (30) · Ovarian Neoplasms (24) · Pancreatic Neoplasms (24) · Stomach Neoplasms (21) · Lung Neoplasms (20) · Squamous Cell Carcinoma of Head and Neck (20) · Brain Neoplasms (19) · Colonic Neoplasms (19) · Carcinoma, Renal Cell (16) · Triple Negative Breast Neoplasms (16)
Pathological Conditions, Signs and Symptoms (225) · Neoplastic Processes (224) · Pathologic Processes (224) · Neoplasms (176) · Neoplasms by Site (143) · Neoplasms by Histologic Type (96) · Neoplasms, Glandular and Epithelial (74) · Digestive System Neoplasms (64) · Digestive System Diseases (63) · Skin Diseases (61) · Skin and Connective Tissue Diseases (61) · Gastrointestinal Diseases (53) · Carcinoma (52) · Gastrointestinal Neoplasms (52) · Neoplasms, Germ Cell and Embryonal (52)
pembrolizumab (23) · Cyclophosphamide (12) · Nivolumab (11) · aldesleukin (10) · Paclitaxel (8) · Gemcitabine (7) · Radiosurgery (7) · fludarabine (7) · Bevacizumab (6) · Irinotecan (6) · 130-nm albumin-bound paclitaxel (5) · Drug Therapy (5) · Fluorouracil (5) · Interleukin-2 (5) · Leucovorin (5)
National Cancer Institute (NCI) (11) · Memorial Sloan Kettering Cancer Center (9) · Eli Lilly and Company (8) · Duke University (6) · Incyte Corporation (5) · Symphogen A/S (5) · Akamis Bio (4) · City of Hope Medical Center (4) · Incyte Biosciences International Sàrl (4) · Mirati Therapeutics Inc. (4) · Verastem, Inc. (4) · NKGen Biotech, Inc. (3) · invoX Pharma Limited (3) · Artios Pharma Ltd (2) · Centre Leon Berard (2)
United States (174) · France (16) · United Kingdom (15) · China (14) · Canada (13) · Spain (12) · Australia (11) · Netherlands (8) · Belgium (7) · Italy (7) · South Korea (7) · Germany (5) · Japan (5) · Taiwan (4) · Poland (3)
Steven A Rosenberg, M.D. (5) · Darell D. Bigner, MD, PhD (4) · David S. Schrump, MD (3) · Jana Portnow, MD (3) · Lillian Siu, MD, FRCPC (3) · Hagop Youssoufian, MD (2) · Herbert K. Lyerly, MD (2) · John E. Janik, MD (2) · MD Verastem (2) · Max W. Sung, MD (2) · Nancy E. Kemeny, MD (2) · Paula R Pohlmann, MD, MSc, PhD (2)
PMID 36897458, PMID 12082455, PMID 12082456, PMID 16009951, PMID 16533779, PMID 17985341, PMID 17987262, PMID 19060590, PMID 19233901, PMID 19372041, PMID 19602035, PMID 19735988, PMID 20595147, PMID 21367608, PMID 21784628, PMID 21850464, PMID 23377668, PMID 23861247, PMID 24711549, PMID 24875132, PMID 24943235, PMID 25175099, PMID 25614945, PMID 25695221, PMID 28261651, PMID 28408243, PMID 29151359, PMID 29290249, PMID 29438373, PMID 33243800, PMID 33492568, PMID 33660194, PMID 34161704, PMID 34264412, PMID 34499416, PMID 34793719, PMID 34844977, PMID 35167329, PMID 35404402, PMID 35658005, PMID 36271158, PMID 36316061, PMID 36330525, PMID 36342102, PMID 36471036, PMID 36545256, PMID 36546659, PMID 37099736, PMID 37214210, PMID 37327468
2016 (4), P30CA033572 (4), 2015 (3), 2017 (1), 2018 (1), 2023 (1), P30CA008748 (1), P30CA014520 (1), P30CA015083 (1), P30CA022453 (1), P30CA043703 (1), P30CA054174 (1), P30CA068485 (1), P30CA069533 (1), P30CA072720 (1)